Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
June 7th, 2019
12.3K views
The goal of this protocol is to describe a new breast cancer modeling approach based on the intraductal injection of Cre-expressing adenovirus into mouse mammary glands. This approach allows both cell-type- and organ-specific manipulation of oncogenic events in a temporally controlled manner.
Overview
This protocol describes a novel approach for modeling breast cancer through the intraductal injection of Cre-expressing adenovirus into mouse mammary glands. This method enables specific manipulation of oncogenic events in a controlled manner.
Key Study Components
Area of Science
- Breast cancer research
- Mouse model development
- Oncogenic manipulation
Background
- Current methods for modeling breast cancer often require extensive mouse breeding.
- There is a need for techniques that allow for cell-type specific modeling.
- This protocol aims to address these challenges.
- It focuses on the use of adenoviral vectors for targeted gene manipulation.
Purpose of Study
- To create a new mouse model that mimics human breast cancer development.
- To facilitate research on different subsets of mammary epithelial cells.
- To provide a method that reduces the need for complex breeding strategies.
Methods Used
- Preparation and maintenance of floxed mice.
- Administration of anesthesia and analgesia prior to surgery.
- Intraductal injection of Cre-expressing adenovirus.
- Monitoring of surgical procedures for safety and efficacy.
Main Results
- Successful generation of breast cancer mouse models.
- Demonstrated cell-type specific manipulation of oncogenic events.
- Reduced complexity in model generation compared to traditional methods.
- Potential for further studies on breast cancer progression.
Conclusions
- This protocol provides a novel approach to breast cancer modeling.
- It allows for precise control over oncogenic events in specific cell types.
- The method can enhance understanding of breast cancer biology.
Frequently Asked Questions
What is the main advantage of this protocol?
The protocol allows for cell-type specific modeling of breast cancer without extensive mouse breeding.
How does the adenovirus contribute to the model?
The adenovirus enables targeted manipulation of oncogenic events in the mammary glands.
What are floxed mice?
Floxed mice are genetically modified mice with specific genes flanked by loxP sites, allowing for targeted gene editing.
What is the significance of using Meloxicam?
Meloxicam is used as an analgesic to manage pain during and after the surgical procedure.
Can this method be applied to other types of cancer?
While this protocol focuses on breast cancer, similar techniques may be adapted for other cancers with appropriate modifications.
What are the implications of this research?
This research could lead to better understanding and treatment options for breast cancer through improved modeling techniques.
Executive Industry Relevance
Cell-type and organ-specific modeling of breast cancer in mice is critical for de-risking early discovery and clarifying the mechanistic origins of tumorigenesis. The intraductal injection of Cre-expressing adenovirus enables precise temporal and spatial control of oncogenic events, supporting predictive confidence in target validation and disease modeling. This approach streamlines model generation, reducing breeding complexity and enhancing portfolio flexibility for translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of oncogenic pathways in defined mammary epithelial cell subsets.
- Supports functional target validation by isolating cell-of-origin effects in tumorigenesis.
- Facilitates mechanistic de-risking by allowing temporal control of cancer induction.
- Improves predictive confidence for downstream target prioritization.
Screening & Assay Development
- Generates validated, cell-type specific in vivo models for compound screening.
- Provides reproducible and standardized tumor initiation for assay development.
- Enables quantitative tracking of genetically marked tumor cells via reporter systems.
- Supports scalable model generation without extensive breeding pipelines.
Translational & Preclinical Research
- Aligns preclinical models with human disease heterogeneity by targeting distinct epithelial lineages.
- Enables longitudinal tracking of tumor progression and cell fate using reporter-positive cells.
- Supports risk-adjusted advancement decisions by modeling disease-relevant mechanisms.
- Facilitates continuity from discovery through preclinical validation with traceable genetic events.
Pipeline & Workflow Integration
This method integrates at the interface of early discovery and preclinical model development, enabling rapid generation of disease-relevant mouse models for target validation and mechanistic studies.
- Discovery Biology: Provides a platform for hypothesis testing on cell-of-origin and oncogenic event interactions.
- Screening: Delivers reproducible, cell-type specific tumor models for robust compound evaluation.
- Analytics: Enables quantitative measurement of tumor cell populations via flow cytometry and reporter tracking.
- Translational Research: Bridges discovery and preclinical phases by modeling human-relevant tumor heterogeneity.
- Enterprise Reuse: Offers a modular, promoter-driven system adaptable to various genetic backgrounds and research questions.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in breast cancer modeling.
- Operational Value: Streamlines model generation, enhances reproducibility, and minimizes breeding requirements.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling targeted, rapid model deployment.
- Portfolio Impact: Supports risk-adjusted prioritization and flexible advancement of discovery programs.
Implementation Considerations
- Requires expertise in mouse surgery, viral vector handling, and genetic model design.
- Needs access to flow cytometry and imaging infrastructure for reporter-based analysis.
- Demands rigorous cross-team standardization of injection and monitoring protocols.
- Adaptable to different mammary epithelial subpopulations via promoter selection.
- Potential hazards include viral exposure and technical variability in injection success.
Biopharma FAQs
Why does null hypothesis testing matter for Cre-adenovirus tumor induction?
Null hypothesis testing enables teams to rigorously assess whether observed tumorigenesis is specifically due to targeted genetic manipulation in defined mammary epithelial cells, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit the intraductal injection workflow?
By using cell-type specific promoters and temporal control, the protocol isolates the effects of oncogenic events in distinct mammary cell populations, clarifying causal relationships and supporting mechanistic de-risking in the discovery pipeline.
What do quantitative YFP reporter measurements enable in this model?
Quantitative tracking of YFP-positive cells via flow cytometry allows precise monitoring of tumor cell populations, enabling comparative analysis of tumor progression and response to interventions across experimental conditions.
Why are replication requirements critical for cross-functional model deployment?
Consistent replication of intraductal injection and tumor induction ensures model reliability, facilitating cross-team data integration and supporting collaborative decision-making in multi-site R&D environments.
What statistical analysis capabilities are required before implementing flow cytometry readouts?
Robust statistical tools are needed to analyze reporter-positive cell frequencies, compare experimental groups, and validate the significance of observed differences, ensuring data-driven advancement decisions in the discovery pipeline.
